Dezvoltarea biosimilarelor și hormonului de creștere biosimilar

Corina Scutari; Liliana Rusnac; Vladimir Valica; Mihail Todiras; Radu Cazacu

Autori

Corina Scutari Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0001-5390-5493
Liliana Rusnac Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0001-8522-6209
Vladimir Valica Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0002-1068-5504
Mihail Todiras Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0000-0002-9373-4753
Radu Cazacu Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“ https://orcid.org/0009-0006-7427-8939

Cuvinte cheie:

biosimilar, hormon de creștere, dezvoltare, producere

Rezumat

În acest articol s-a efectuat prezentarea informativă despre dezvoltarea biosimilarelor și hormonului de creștere biosimilar în Europa și Republica Moldova, în urma selectării și analizei a 37 de surse bibliografi ce din baza de date PubMed și din revistele de specialitate. Hormonul de creștere uman a fost aprobat de Agenția Europeană pentru Medicamente (EMA) în 2006 ca primul medicament biosimilar din lume. Terapia cu hormonul de creștere recombinant este aprobată în prezent pentru defi citul de hormon de creștere, sindromul Turner, insuficiența renală cronică, la copii/adolescenți născuți mici pentru vârsta gestațională și sindromul PraderWilli. Totodată, terapia cu biosimilare este foarte costisitoare. În Republica Moldova, dar și în Europa de Est accesibilitatea medicamentelor biologice este una extrem de redusă din cauza lipsei unor producători locali sau regionali. Dezvoltarea în Republica Moldova a ramurii de producere a biosimilarelor, printre care și hormonul de creștere biosimilar, va fi o opțiune atractivă și farmacoeconomic avantajoasă pentru arsenalul terapeutic.

Referințe

1. Allocati E., Bertele V., Gerardi C., Garattini S. Clinical evidence supporting the marketing authorization of biosimilars in Europe. Eur J Clin Pharmacol, 2020, 76(4), 557-566. https://doi.org/10.1007/s00228-019-02805-y

2. Al-Sabbagh A., Olech E., Mcclellan J., Kirchhoff C. Development of biosimilars. Semin Arthritis Rheum, 2016, 45(5 Suppl), 11-18. https://doi.org/10.1016/j.semarthrit.2016.01.002

3. Bonovas S., Peyrin-Biroulet L., Danese S. Clinical development of biologicals and biosimilars - safety concerns. Expert Rev Clin Pharmacol, 2017, 10(6), 567-569. https://doi.org/10.1080/17512433.2017.1293522

4. Bui L., Hurst S., Finch G., Ingram B., Jacobs I., Kirchhoff C. Key considerations in the preclinical development of biosimilars. Drug Discov Today, 2015, nr. 20, 3-15. https://doi.org/10.1016/j.drudis.2015.03.011

5. Cauchy M., Heff ord M. Excipient exchange in the comparison of preparations of the same biologic made by diff erent manufacturing processes: an exploratory study with recombinant human growth hormone (rhGH). Biologicals, 2010, 38(6), 637-643. https://doi.org/10.1016/j.biologicals.2010.07.005

6. Covic A., Kuhlmann M. Biosimilars: recent developments. Int Urol Nephrol, 2007, 39(1), 261-266. https://doi.org/10.1007/s11255-006-9167-5

7. Höybye C., Beck-Peccoz P., Murray R., Simsek S., Stalla G. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone defi ciency: results from an international, post-marketing surveillance study. Pituitary, 2021, 24(4), 622-629. https://doi.org/10.1007/s11102-021-01139-2

8. Ishii-Watabe A., Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet, 2019, 34(1), 64-70. https://doi.org/10.1016/j.dmpk.2018.11.004

9. Lavakumar R., Alyson P., Bojan D. Connectivity maps for biosimilar drug discovery in venoms: the case of Gila monster venom and the anti-diabetes drug Byetta. Toxicon, 2013, nr. 69, 160-167. https://doi.org/10.1016/j.toxicon.2013.03.018

10. Li E, Abbas R, Jacobs I, Yin D. Considerations in the early development of biosimilar products. Drug Discov Today, 2015, nr. 20, Suppl 2, 1-9. https://doi.org/10.1016/j.drudis.2014.12.017

11. López-Siguero J., Pfäffl e R., Chanson P., Szalecki M. Ten years' clinical experience with biosimilar human growth hormone: a review of effi cacy data. Drug Des Devel Ther, 2017, 16, 1489-1495. https://doi.org/10.2147/DDDT.S130320

12. Martin W. Therapy with recombinant growth hormone. MMW Fortschr Med, 2007, 149(23), 41-43. https://doi.org/10.1007/BF03365078

13. Meena S. Clinical development of biosimilars: an evolving landscape. Bioanalysis, 2013, 5(5), 575-586. https://doi.org/10.4155/bio.13.5

14. Mysler E. Biosimilars: clinical interpretation and implications for drug development. Curr Rheumatol Rep, 2015, 17(2) p. 8. https://doi.org/10.1007/s11926-014-0483-y

15. Nabhan Ch., Mato A., Feinber B. Biosimilars in Oncology in the United States: A Review. JAMA Oncol, 2018, 4(2), 241-247. https://doi.org/10.1001/jamaoncol.2017.2004

16. Oliveira Ascef B., Freitas Lopes A., Coelho De Soárez P. Health technology assessment of biosimilars worldwide: a scoping review. Health Res Policy Syst, 2020, vol. 26, nr. 18(1), p. 95. https://doi.org/10.1186/s12961-020-00611-y

17. Oza B., Radhakrishna S., Pipalava P., Jose V. Pharmacovigilance of biosimilars - Why is it diff erent from generics and innovator biologics? J Postgrad Med, 2019, 65(4), 227-232. https://doi.org/10.4103/jpgm.JPGM_109_19

18. Pavlovic M., Girardin E., Kapetanovic L., Ho K. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res, 2008, 69(1), 14-21. https://doi.org/10.1159/000111790

19. Pekka K., Leon Van A., Elena W., Thijs G. Interchangeability of Biosimilars: A European Perspective. BioDrugs, 2017, 31(2), 83-91. https://doi.org/10.1007/s40259-017-0210-0

20. Perpoil A., Grimandi G., Birklé S., Simonet J., Chiffoleau A. Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant? Int J Environ Res Public Health, 2020, 18(1), p. 186. https://doi.org/10.3390/ijerph18010186

21. Pfäffl e R., Bidlingmaier M., Kreitschmann-Andermahr I., Land C. Safety and Eff ectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study. Horm Res Paediatr, 2020, 93(3), 154-163. https://doi.org/10.1159/000508190

22. Rais I. When two do the same, it is not the same. Requirements for development and quality of biosimilars. Pharm Unserer Zeit, 2012, 41(6), 453-460. https://doi.org/10.1002/pauz.201200491

23. Romer T., Peter F., Saenger P., Starzyk J., Koehler B., Korman E., Walczak M. Effi cacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest, 2007, 30(7), 578-89. https://doi.org/10.1007/BF03346352

24. Saenger P. Biosimilar growth hormone. Indian J Pediatr. 2012, 79(1), 92-98. https://doi.org/10.1007/s12098-011-0610-y

25. Saenger P. Current status of biosimilar growth hormone. Int J Pediatr Endocrinol, 2009, 370-379. https://doi.org/10.1186/1687-9856-2009-370329

26. Saenger P. Ten years of biosimilar recombinant human growth hormone in Europe. Drug Des Devel Ther, 2017, 11, 1505-1507. https://doi.org/10.2147/DDDT.S130317

27. Schellekens H. When biotech proteins go off -patent. Trends Biotechnol, 2004, 22(8), 406-410. https://doi.org/10.1016/j.tibtech.2004.06.003

28. Schiestl M., Zabransky M., Sörgel F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Des Devel Ther, 2017, nr. 11, 1509-1515. https://doi.org/10.2147/DDDT.S130318

29. Shashank R. Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India, 2018, 44-47.

30. Soldatov A., Avdeeva J., Kryuchkov N., Skosyreva E. Safety concerns of biosimilar hormone products. Curr Med Res Opin, 2019, 35(6), 1003-1009. https://doi.org/10.1080/03007995.2018.1552041

31. Sreedhar S., Hillel P., Gillian R. Pharmacovigilance of Biologics in a Multisource Environment. J Manag Care Spec Pharm, 2017, 23(12), 1249-1254. https://doi.org/10.18553/jmcp.2017.23.12.1249

32. Stergiopoulos S., Brown A., Grampp G., Thomas F. Identifying and Quantifying the Accuracy of Product Name Attribution of US-Sourced Adverse Event Reports in MedWatch of Somatropins and Insulins. Ther Innov Regul Sci, 2015, 49(5), 706-716. https://doi.org/10.1177/2168479015578156

33. Tamilvanan S., Livingston N., Biswanath S. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J Drug Target, 2010, 18(7), 489-498. https://doi.org/10.3109/10611861003649746

34. Toff oletto O., Afi une J., Thiemann J., Khandave S. Comparative pharmacokinetic and pharmacodynamic evaluation between a new biosimilar and reference recombinant human growth hormone. Growth Horm IGF Res, 2016, nr. 30-31, 31-36. https://doi.org/10.1016/j.ghir.2016.09.003

35. Zelenetz A., Becker P. The Role of Biosimilars. J Natl Compr Canc Netw, 2016, 14(5 Suppl), 626-629. https://doi.org/10.6004/jnccn.2016.0178

36. Webster Ch., Wong A., Woollett G. An Effi cient Development Paradigm for Biosimilars. BioDrugs, 2019, 33(6), 603-611. https://doi.org/10.1007/s40259-019-00371-4

37. Wolff -Holz E., Tiitso K., Vleminckx C., Weise M. Evolution of the EU Biosimilar Framework: Past and Future. BioDrugs, 2019, 33(6), 621-63 https://doi.org/10.1007/s40259-019-00377-y

Dezvoltarea biosimilarelor și hormonului de creștere biosimilar

Autori

Cuvinte cheie:

Rezumat

Referințe

Descărcări

Publicat

Număr

Secțiune

Licență

Cum cităm

Cele mai citite articole ale aceluiași autor(i)

Articole similare

Limbă

issn

oa cc-by-nc-sa

road-issn

crossref member

ibn